Skip to main content
Erschienen in: Breast Cancer Research and Treatment 1/2009

01.11.2009 | Brief Report

Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells

verfasst von: Hongjie Pan, Luke S. Wanami, Thusitha R. Dissanayake, Robin E. Bachelder

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The axon repulsion factor semaphorin3A (SEMA3A) and its receptor neuropilin-1 (NP-1) are expressed in breast tumor cells, and function as suppressors of tumor cell migration. Based on the knowledge that both SEMA3A and the α2β1 integrin suppress breast tumor cell migration, we studied the impact of SEMA3A signaling on α2β1 integrin expression/function. The incubation of breast tumor cells with SEMA3A increased α2 and β1 integrin levels, and stimulated tumor cell adhesion to the α2β1-binding matrix protein collagen I. Conversely, reducing SEMA3A expression in breast tumor cells decreased α2β1 levels and collagen adhesion. The ability of SEMA3A to increase tumor cell adhesion to collagen was dependent on both the SEMA3A receptor NP-1 and the glycogen synthase kinase-3. The incubation of breast tumor cells with SEMA3A disrupted the actin cytoskeleton, and reduced both tumor cell migratory and invasive behavior. Importantly, using an α2β1-neutralizing antibody, we demonstrated that SEMA3A suppression of tumor cell migration is dependent on α2β1. Our studies indicate that expression of the α2β1 integrin, a suppressor of metastatic breast tumor growth, is stimulated in breast tumor cells by an autocrine SEMA3A pathway.
Literatur
3.
Zurück zum Zitat Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M (1999) Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146(1):233–242. doi:10.1083/jcb.146.1.233 CrossRefPubMed Miao HQ, Soker S, Feiner L, Alonso JL, Raper JA, Klagsbrun M (1999) Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. J Cell Biol 146(1):233–242. doi:10.​1083/​jcb.​146.​1.​233 CrossRefPubMed
4.
Zurück zum Zitat Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F et al (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424(6947):391–397. doi:10.1038/nature01784 CrossRefPubMed Serini G, Valdembri D, Zanivan S, Morterra G, Burkhardt C, Caccavari F et al (2003) Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 424(6947):391–397. doi:10.​1038/​nature01784 CrossRefPubMed
5.
Zurück zum Zitat Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ et al (2003) Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63(17):5230–5233PubMed Bachelder RE, Lipscomb EA, Lin X, Wendt MA, Chadborn NH, Eickholt BJ et al (2003) Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Res 63(17):5230–5233PubMed
7.
Zurück zum Zitat Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM (2002) The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 161(1):337–344PubMed Chen J, Diacovo TG, Grenache DG, Santoro SA, Zutter MM (2002) The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am J Pathol 161(1):337–344PubMed
9.
Zurück zum Zitat Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R et al (2005) Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 171(4):717–728. doi:10.1083/jcb.200503144 CrossRefPubMed Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R et al (2005) Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol 171(4):717–728. doi:10.​1083/​jcb.​200503144 CrossRefPubMed
10.
11.
Zurück zum Zitat Zutter MM, Krigman HR, Santoro SA (1993) Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 142(5):1439–1448PubMed Zutter MM, Krigman HR, Santoro SA (1993) Altered integrin expression in adenocarcinoma of the breast. Analysis by in situ hybridization. Am J Pathol 142(5):1439–1448PubMed
12.
Zurück zum Zitat Zutter MM, Mazoujian G, Santoro SA (1990) Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137(4):863–870PubMed Zutter MM, Mazoujian G, Santoro SA (1990) Decreased expression of integrin adhesive protein receptors in adenocarcinoma of the breast. Am J Pathol 137(4):863–870PubMed
13.
Zurück zum Zitat Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter R (1995) In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br J Surg 82(9):1192–1196. doi:10.1002/bjs.1800820914 CrossRefPubMed Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter R (1995) In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br J Surg 82(9):1192–1196. doi:10.​1002/​bjs.​1800820914 CrossRefPubMed
14.
Zurück zum Zitat Lochter A, Navre M, Werb Z, Bissell MJ (1999) Alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol Biol Cell 10(2):271–282PubMed Lochter A, Navre M, Werb Z, Bissell MJ (1999) Alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol Biol Cell 10(2):271–282PubMed
15.
Zurück zum Zitat Keely PJ, Fong AM, Zutter MM, Santoro SA (1995) Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci 108(Pt 2):595–607PubMed Keely PJ, Fong AM, Zutter MM, Santoro SA (1995) Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci 108(Pt 2):595–607PubMed
16.
18.
Zurück zum Zitat Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ et al (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7(10):793–803. doi:10.1016/S1074-5521(00)00025-9 CrossRefPubMed Coghlan MP, Culbert AA, Cross DA, Corcoran SL, Yates JW, Pearce NJ et al (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7(10):793–803. doi:10.​1016/​S1074-5521(00)00025-9 CrossRefPubMed
20.
Zurück zum Zitat DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA (1993) Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol 122(3):729–737. doi:10.1083/jcb.122.3.729 CrossRefPubMed DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA (1993) Maximal migration of human smooth muscle cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. J Cell Biol 122(3):729–737. doi:10.​1083/​jcb.​122.​3.​729 CrossRefPubMed
21.
Zurück zum Zitat Lynch L, Vodyanik PI, Boettiger D, Guvakova MA (2005) Insulin-like growth factor I controls adhesion strength mediated by alpha5 beta1 integrins in motile carcinoma cells. Mol Biol Cell 16(1):51–63. doi:10.1091/mbc.E04-05-0399 CrossRefPubMed Lynch L, Vodyanik PI, Boettiger D, Guvakova MA (2005) Insulin-like growth factor I controls adhesion strength mediated by alpha5 beta1 integrins in motile carcinoma cells. Mol Biol Cell 16(1):51–63. doi:10.​1091/​mbc.​E04-05-0399 CrossRefPubMed
22.
23.
24.
Zurück zum Zitat Lepelletier Y, Smaniotto S, Hadj-Slimane R, Villa-Verde DM, Nogueira AC, Dardenne M et al (2007) Control of human thymocyte migration by neuropilin-1/semaphorin-3A-mediated interactions. Proc Natl Acad Sci USA 104(13):5545–5550. doi:10.1073/pnas.0700705104 CrossRefPubMed Lepelletier Y, Smaniotto S, Hadj-Slimane R, Villa-Verde DM, Nogueira AC, Dardenne M et al (2007) Control of human thymocyte migration by neuropilin-1/semaphorin-3A-mediated interactions. Proc Natl Acad Sci USA 104(13):5545–5550. doi:10.​1073/​pnas.​0700705104 CrossRefPubMed
25.
Zurück zum Zitat Herman JG, Meadows GG (2007) Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30(5):1231–1238PubMed Herman JG, Meadows GG (2007) Increased class 3 semaphorin expression modulates the invasive and adhesive properties of prostate cancer cells. Int J Oncol 30(5):1231–1238PubMed
26.
Zurück zum Zitat Castellani V, Chedotal A, Schachner M, Faivre-Sarrailh C, Rougon G (2000) Analysis of the L1-deficient mouse phenotype reveals cross-talk between Sema3A and L1 signaling pathways in axonal guidance. Neuron 27(2):237–249. doi:10.1016/S0896-6273(00)00033-7 CrossRefPubMed Castellani V, Chedotal A, Schachner M, Faivre-Sarrailh C, Rougon G (2000) Analysis of the L1-deficient mouse phenotype reveals cross-talk between Sema3A and L1 signaling pathways in axonal guidance. Neuron 27(2):237–249. doi:10.​1016/​S0896-6273(00)00033-7 CrossRefPubMed
Metadaten
Titel
Autocrine semaphorin3A stimulates alpha2 beta1 integrin expression/function in breast tumor cells
verfasst von
Hongjie Pan
Luke S. Wanami
Thusitha R. Dissanayake
Robin E. Bachelder
Publikationsdatum
01.11.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 1/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0179-y

Weitere Artikel der Ausgabe 1/2009

Breast Cancer Research and Treatment 1/2009 Zur Ausgabe

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.